Claim Ledger
75% answered
Did management answer the analysts?
12 analyst questions audited, 1 evaded or deflected.
View Claim Ledger →
Apollohosp Ltd — Q3 FY24
Apollo Hospitals reported a strong Q3 FY24 with consolidated revenue of INR 4,851 crore (+14% YoY) and EBITDA of INR 614 crore (+21% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Apollo Hospitals reported a strong Q3 FY24 with consolidated revenue of INR 4,851 crore (+14% YoY) and EBITDA of INR 614 crore (+21% YoY). PAT surged 56% YoY to INR 245 crore, driven by robust healthcare services growth (12% YoY) and a significant milestone: Apollo HealthCo achieved break-even a quarter early. Hospital occupancy stood at 66%, with ARPOB up 10% to INR 56,368. Management guided for 200 bps margin improvement in healthcare services over the next few quarters, supported by volume growth and cost rationalization. The 24/7 digital platform is expected to break even in 6-8 quarters, with new revenue streams like insurance distribution and digital therapeutics. A 2,000-bed expansion plan over four years is underway. Key risk: new bed additions may temporarily pressure margins if ramp-up is slower than expected.
अपोलो हॉस्पिटल्स ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कुल कमाई 4,851 करोड़ रुपये रही, जो पिछले साल से 14% ज्यादा है। कंपनी का मुनाफा 245 करोड़ रुपये रहा, जो 56% बढ़ा है। अस्पतालों में 66% बिस्तर भरे रहे और मरीजों से औसत कमाई 10% बढ़कर 56,368 रुपये हो गई। कंपनी की डिजिटल सेवा (अपोलो हेल्थको) ने उम्मीद से पहले ही घाटा खत्म कर लिया। आने वाले समय में कंपनी लागत घटाकर और मरीजों की संख्या बढ़ाकर मुनाफा और सुधारना चाहती है। साथ ही, अगले चार साल में 2,000 नए बिस्तर जोड़े जाएंगे। लेकिन सावधानी: नए बिस्तरों को भरने में देरी हुई तो मुनाफा कम हो सकता है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Margin pressure from new bed additions
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Hospital Occupancy
66%
Flat YoY
Occupancy remained at 66% despite seasonal headwinds and reduction in dialysis volumes.
ARPOB
INR 56,368
+10% YoY
Average revenue per occupied bed increased 10% YoY, driven by pricing and case mix improvements.
24/7 GMV
INR 658 crore
+21% QoQ
Gross merchandise value of the digital platform grew 21% sequentially, with 2 million new users added.
Insurance Revenue Share
43%
+16% YoY
Insurance revenues grew 16% YoY, now contributing 43% of total hospital IP revenue.
What Changed vs Last Quarter
NEW
Healthcare services revenue growth of 15% for FY24
Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%.
NEW
200 bps margin improvement in healthcare services over next few quarters
Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization.
UPDATED
Apollo 24/7 break-even in 6-8 quarters
Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics.
UPDATED
2,000 beds over four years at INR 3,000 crore capex
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
DROPPED
Hospital EBITDA margin expansion of 200 bps
Management expects hospital EBITDA margins to improve by 200 basis points over the next two years, driven by operating leverage and occupancy improvement.
DROPPED
Pharmacy omni-channel revenue of INR 10,000 crore and 6%+ EBITDA margin
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
NEW RISK
Margin pressure from new bed additions
New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.
NEW RISK
Seasonality and one-off events impacting growth
Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.
NEW RISK
Slowdown in 24/7 daily active users
Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.
NEW RISK
Regulatory risk from kidney racket allegations
Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made.
RISK GONE
Delayed monsoon impacted medical admissions in South India
Inpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.
RISK GONE
New hospital ramp-up may pressure near-term margins
Analyst raised concern that new bed additions (Pune, Kolkata, Hyderabad) could drag margins until they reach breakeven in 12-18 months.
RISK GONE
Competitive intensity in metro markets
Analyst questioned whether expansion in metros (where supply is strong) is prudent versus non-metros where Apollo has an early-mover advantage.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
The digital health platform is expected to achieve operational breakeven by the fourth quarter of FY24.
Mentioned in Q1 FY24, Q2 FY24
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
Fast read
Guidance and risk preview
Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%.
New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.
View Risks →